The threat of a widespread swine flu outbreak weighed on the markets Monday, and for good reason: Even if the virus is contained, it's still likely to put a crimp on spending for a wide array of goods.
Concerns that the swine flu could reach pandemic proportions sent money moving. Who wins and who loses?
Swine Flu: global pandemic or paranoia? President Obama said the health emergency declaration was merely a prudent measure. But many pharmaceutical stocks were sharply higher Monday in reaction to flu outbreaks — and the gains seemed to ripple through the sector.
As author of World Event Trading, I did an entire section on infectious diseases from the 1918 Spanish Flu to Bird Flu. The recent outbreak of Swine Flu is generating headlines and concerns globally......Critical point: fear of the disease is the biggest driver of behavior and societal changes due to the outbreak.
Financials continue to lead the weakness today on the heels of Bank of America’s earnings report. In late-morning trading, B of A and Citigroup are now down 15 percent each, while many other regional banks are 11 to 15 percent lower.
In this Web Extra, Pete Najarian talks Pharma takeovers. What's on his radar?
An estimated 20 million or so Americans have the disease, which many experts call an epidemic. It costs this country tens of billions of dollars a year to deal with it. And several biopharma and monitoring device companies are racing to grab a bigger piece of this fast-growing, sugar-free pie.
Breakthrough diabetes treatments may be on the horizon. What companies stand to win?
A number of takeover rumors have been making the rounds, an encouraging sign that capitalistic optimism is returning to the markets.
OptionMonster Jon Najarian reveals where he's spotted some unusually bullish action.
The Pit Boss is seeing explosive options action in a drug stock. Find out which one!
Both Pete and Jon Najarian are seeing some unusual options action. What do they make of it?
Plus, Cramer discusses credit-card and drug stocks, as well as the housing bottom.
The OptionMonster is seeing unusual action in two stocks. What does he make of it?
My first week on Twitter has gone pretty well. Despite some Twitter trouble (or should that be twubble?) with website capacity, I've picked up more than 75 followers already.
Normally, the folks at GlaxoSmithKline keep us tightly in the loop when there's news. So, I'm a bit surprised that it took a "tweet" on Twitter this morning to learn that four days ago the company put out a press release that has "Pharma's Market" written all over it.
Japan and Januvia. No, it's not a country—not even a fictional one—even though it sounds like "Genovia" in "The Princess Diaries." It's a diabetes drug from Merck.
The number of job cuts continued to soar in February 2009, reflecting the worsening US recession.
More companies announced layoffs this week as the employment picture continued to dim. JPMorgan Chase and Chesapeake Energy were among the latest names on Thursday to announce job cuts.
Vinesh writes, “What is the reason why the Exxon stock is not doing well lately. Crude oil is going up where as Exxon share price is not keeping pace with the increase in crude?"